India, June 2 -- Wockhardt's Zaynich has got US FDA approval and Indian CDSCO marketing authorisation for treating complicated urinary tract infections.

It is a novel injectable antibiotic combining cefepime and zidebactam.

The drug is the first fully indigenously developed Indian new chemical entity to secure US FDA approval.

It offers a potent option against multidrug-resistant gram-negative bacteria amid a thinning global antibiotic pipeline.

Indian pharmaceutical and biotechnology company Wockhardt has announced the regulatory approval of Zaynich, a breakthrough novel antibiotic aimed at treatment of complicated urinary tract infection (cUTI), including pyelonephritis, in adults.

Late last week, the United States Food and Drug Ad...